title: The possibility of clinical application of the thromboxane A2 synthase inhibitor, ozagrel, for the treatment and prevention of preeclampsia: a preliminary report.
abstract: OBJECTIVE
  This study was performed to investigate whether the TXA2 synthase inhibitor, ozagrel, was effective in the treatment and prevention of pre-eclampsia.
  
  
  METHODS
  Ozagrel was administrated therapeutically to 4 severely pre-eclamptic women, and prophylactically to 5 pregnant women with histories of severe preeclampsia and complications.
  
  
  RESULTS
  The therapeutic administration (TA) of ozagrel improved hypertension and proteinuria. Two patients delivered appropriate-for-date (AFD) infants, whereas the other 2 patients delivered light-for-date (LFD) infants. Mean plasma concentrations of TXB2 (plasma TXB2) decreased, whereas plasma 6-keto PGF1 alpha were almost unchanged. The prophylactic administration (PA) of ozagrel prevented the occurrence of preeclampsia in 3 of the 5 patients. All delivered AFD infants. The duration of pregnancy was prolonged more than that of previous pregnancies in all patients. Plasma TXB2 decreased, whereas plasma 6-keto PGF1 alpha increased.
  
  
  CONCLUSIONS
  PA prevented preeclampsia and intrauterine growth retardation, whereas TA improved only maternal symptoms. These results might justify a large prospective study to determine whether ozagrel is an effective prophylactic.
authors.affiliation: Department of Obstetrics and Gynecology, Saitama Medical Center, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Seki
authors.forename: K
authors.initials: K
authors.lastname: Kuromaki
authors.forename: S
authors.initials: S
authors.lastname: Takeda
authors.forename: K
authors.initials: K
authors.lastname: Kinoshita
authors.forename: K
authors.initials: K
authors.lastname: Satoh
mesh_terms: D000328:Adult; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008689:Methacrylates / Q000494:pharmacology / Q000627:therapeutic use*; D010865:Pilot Projects; D010974:Platelet Aggregation / Q000187:drug effects; D011225:Pre-Eclampsia / Q000097:blood / Q000188:drug therapy* / Q000517:prevention & control*; D011247:Pregnancy; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D016896:Treatment Outcome
chemical_list: D004791:Enzyme Inhibitors; D008689:Methacrylates; D013930:Thromboxane-A Synthase; C034364:ozagrel